Byetta Wins Out as Add-On Therapy

ADA 2012 — PHILADELPHIA — The GLP-1 receptor agonist exenatide (Byetta) was superior to glimepiride (Amaryl) as an add-on therapy once patients with type 2 diabetes had failed on metformin, researchers found.


< Back to Listings